Celerion Vaccine Development. Global Access. Local Expertise. Learn More

Expertise in Immunogenicity Assessment


Immunogenicity

Immunogenicity influences safety and efficacy of biologic drugs, with consequences ranging up to life-threatening reactions.Celerion has over 30 years’ experience in immunogenicity assessment using various immunoanalytical and cell-based technologies, one of the pioneers of immunogenicity testing from the mid-1990s.


Tiered Approach Geared for Drug Safety

Anti-drug antibody Assays (ADA) are critical to understanding drug immunogenicity as these parameters ultimately impact patients receiving biologics products. This approach ensures all parameters are evaluated.


Sensitivity Drives Multi-tier Immunogenicity Platform Selection

Immungenicity platforms are varied and plentiful, but possess a spectrum of advantages all driven by the particular biologic’s unique characteristics and development needs. The Celerion ScienceTM Team creates immunogenicity strategies across the drug development lifecyle in a customized, adaptive manner.


Complexities Simplified by Celerion Science™

The range of immunogenicity needs is broad but our scientists customize the program specifically tailored to the compound and across species such as rodents, humans, and non-human primates.

Immunogenicity


Development for Neu5Gc Residues

View Article

Immunogenicity


RIA

View Assessment

Immunogenicity


Oncology Antibody Drug

View Assessment

Immunogenicity


Aegyris, Supporting Vaccine

View Poster